Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jul 1;4(3):179-181.
doi: 10.1016/S2055-6640(20)30267-3.

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C

Stephanie Popping  1 , Valeria Cento  2 , Federico García, Francesca Ceccherini-Silberstein, Carole Seguin-Devaux, David Amc Vijver  1 , Charles A Boucher
Affiliations
Editorial

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C

Stephanie Popping et al. J Virus Erad. .

Abstract

The World Health Organization (WHO) has declared that hepatitis C virus (HCV) should be eliminated as a public health threat. A key recommendation to reach this elimination goal, is to reduce new infections by 90% and liver-related mortality by 65%. Highly effective direct-acting antiviral agents (DAA) play a major role in this elimination. Unfortunately, DAA treatment fails approximately 2.5-5% of patients, often in the presence of resistance-associated substitutions (RAS). This could eventually lead to a total number of 1.8-3.6 million first-line DAA failures. RAS may jeopardise the elimination goals for several reasons; most importantly, virus transmission and infection progression will continue. More data are required to handle RAS adequately and identify mutational patterns causing resistance. Currently, sample sizes are small, data are scattered and methods heterogenic. Collaboration is therefore key and a European collaboration, such as HEPCARE, should provide a solution.

Keywords: hepatitis C, direct-acting antivirals, resistance, resistance-associated substitutions, elimination.

PubMed Disclaimer

References

    1. World Health Organization 2017. Global Hepatitis Report 2017 Geneva. Available at: www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ ( accessed April 2018).
    1. Pepin J, Abou Chakra CN, Pepin E et al. . Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010. PLoS One 2014; 9: e99677. - PMC - PubMed
    1. Prati D. Transmission of viral hepatitis by blood and blood derivatives: current risks, past heritage. Dig Liver Dis 2002; 34: 812– 817. - PubMed
    1. Feld JJ, Jacobson IM, Hezode C et al. . Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599– 2607. - PubMed
    1. Hullegie SL, Nichols BE, Rijnders BJ et al. . 2016. Is HCV elimination possible? A modeling study of HIV-positive MSM Conference on Retroviruses and Opportunistic Infections February 2016. Boston, MA, USA. Abstract 536.

Publication types

LinkOut - more resources